Construction of Candida albicans Adhesin-Exposed Synthetic Cells for Preventing Systemic Fungal Infection
Author:
Zhao Zirun1ORCID, Sun Ying1ORCID, Li Mingchun1, Yu Qilin123ORCID
Affiliation:
1. Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin 300071, China 2. Research Center for Infectious Diseases, Nankai University, Tianjin 300350, China 3. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Tianjin 300350, China
Abstract
The development of efficient fungal vaccines is urgent for preventing life-threatening systemic fungal infections. In this study, we prepared a synthetic, cell-based fungal vaccine for preventing systemic fungal infections using synthetic biology techniques. The synthetic cell EmEAP1 was constructed by transforming the Escherichia coli chassis using a de novo synthetic fragment encoding the protein mChEap1 that was composed of the E. coli OmpA peptide, the fluorescence protein mCherry, the Candida albicans adhesin Eap1, and the C-terminally transmembrane region. The EmEAP1 cells highly exposed the mChEap1 on the cell surface under IPTG induction. The fungal vaccine was then prepared by mixing the EmEAP1 cells with aluminum hydroxide gel and CpG. Fluorescence quantification revealed that the fungal vaccine was stable even after 112 days of storage. After immunization in mice, the vaccine resided in the lymph nodes, inducing the recruitment of CD11c+ dendritic cells. Moreover, the vaccine strongly activated the CD4+ T splenocytes and elicited high levels of anti-Eap1 IgG. By the prime-boost immunization, the vaccine prolonged the survival time of the mice infected by the C. albicans cells and attenuated fungal colonization together with inflammation in the kidneys. This study sheds light on the development of synthetic biology-based fungal vaccines for the prevention of life-threatening fungal infections.
Funder
National Natural Science Foundation of China Natural Science Foundation of Tianjin Fundamental Research Funds for the Central Universities
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference59 articles.
1. Immune defence against Candida fungal infections;Netea;Nat. Rev. Immunol.,2015 2. COVID-19-associated fungal infections;Hoenigl;Nat. Microbiol.,2022 3. Roudbary, M., Kumar, S., Kumar, A., Černáková, L., Nikoomanesh, F., and Rodrigues, C.F. (2021). Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID-19 patients. J. Fungi, 7. 4. d’Enfert, C., Kaune, A.K., Alaban, L.R., Chakraborty, S., Cole, N., Delavy, M., Kosmala, D., Marsaux, B., Frois-Martins, R., and Morelli, M. (2021). The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: Current knowledge and new perspectives. FEMS Microbiol. Rev., 45. 5. MRI of CNS fungal infections: Review of aspergillosis to histoplasmosis and everything in between;Starkey;Clin. Neuroradiol.,2014
|
|